Company Information
Industry 制造业
Company Introduction 中山大学达安基因股份有限公司是一家主要从事荧光PCR检测技术技术研究、开发和应用,荧光PCR检测试剂盒和医疗设备的生产和销售以及提供临床检验服务的生物制品公司.公司在分子生物学技术方面,尤其是基因诊断技术及其试剂产品的研制、开发和应用上始终处于领先地位.2010年公司新产品甲型H1N1流感病毒核酸检测试剂盒(PCR-荧光探针法)被确认为国家重点新产品,公司获得广东省创新企业、广东省自主创新100强企业等荣誉称号.2010年公司及控股子公司共获得包括血源筛查HBV、HCV、HIV-1病毒核酸检测试剂盒(PCR-荧光探针法)、21三体和性染色体多倍体检测试剂盒(荧光PCR毛细管电泳法)、乙型肝炎病毒YMDD基因突变检测试剂盒(PCR-反向点杂交法)、乙型肝炎病毒前C区/BCP区突变检测试剂盒(PCR-反向点杂交法)、乙型肝炎病毒基因分型检测试剂盒(PCR-反向点杂交法)等在内的16项国家食品药品监督管理局颁发的医疗器械注册证。
Main Business 荧光PCR检测技术研究、开发和应用,包括生产和销售荧光PCR检测试剂盒和相关检测设备,并提供与临床基因诊断相关的技术咨询服务。
Legal Representative 韦典含
Top Executives
董事长:韦典含
副董事长:陈宏威
董事:梁志坤,陈宏威,黄志征,韦典含,朱琬瑜,张为结
独立董事:范建兵,裴新春,侯向京
Top 5 Shareholder
Shareholder name Nature Holding Date
广州广永科技发展有限公司流通A股16.63%31/03/2025
广州生物医药与健康产业投资有限公司流通A股10.00%31/03/2025
广州金融控股集团有限公司流通A股5.00%31/03/2025
中国银行股份有限公司-华宝中证医疗交易型开放式指数证券投资基金流通A股2.28%31/03/2025
何蕴韶流通A股1.82%31/03/2025
Company Secretary 曾俊
Solicitors 国信联合律师事务所
Auditors 广东羊城会计师事务所有限公司
Tel No 020-32290420
Fax No 020-32290231
Website www.daangene.com
Email zhangbin@daangene.com;zengyuting@daangene.com;web@daangene.com;zengyuting@daangene.com
Company Address
Register: 广东省广州市高新区科学城香山路19号
Office: 广东省广州市高新区科学城香山路19号
Listing Date 09/08/2004
Shares Capital
Shares Capital: 1,403,446,032
Total A Share: 1,403,446,032
Listed A Share: 1,403,446,032
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.660
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 5.615
Market Capitalization(RMB) 8.659B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.